SLNO — SOLENO THERAPEUTICS INC (Healthcare >> Biotechnology)
SLNO FAQ
What is SLNO's P/E ratio?
SOLENO THERAPEUTICS INC (SLNO) currently trades at a P/E ratio of 27.42.
What is SLNO's ROE?
SOLENO THERAPEUTICS INC reports a Return on Equity (ROE) of 19.37%.
What is SLNO's dividend yield?
SOLENO THERAPEUTICS INC offers a dividend yield of 0.00%.
What is SLNO's Deepscope Quality Score?
Deepscope rates SLNO's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SLNO?
Deepscope's AI Timing Score for SLNO is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SLNO belong to?
SOLENO THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 53.01
Price
0.02
(0.04%)
Day Change
|
|
|---|
SLNO มีคุณภาพโดยรวมดีมาก ( คะแนนปัจจัยพื้นฐาน = 85) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ยังไม่ดีนัก สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร พอใช้ , ...
| ปัจจัยทางคุณภาพ |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.09 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
2195
|
| Magic Formula Rank by ROE |
2195
|
| Magic Formula Rank by ROIC |
1846
|
| Price | 53.01 |
| PBV / Sector |
5.57 / 4.79
|
| Earning Per Share | 1.84 |
| PE / Sector |
27.42 / 18.05
|
| PEG or PE/Growth / Sector |
-2.00 / 0.62
|
| Average 1M Daily Value |
94.50 M
|
| Average 1W Daily Value |
108.47 M
GREAT
|
| ปัจจัยทางเทคนิค |
|
71% |
| สุขภาพทางการเงิน |
|
45% |
| ประสิทธิภาพการทำกำไร |
|
66% |
| ผลตอบแทนต่อผู้ถือหุ้น |
|
4% |
| รายละเอียดการจดทะเบียน |
| Analyze Date | 2026-06-12 09:43:20 |
| Symbol | SLNO |
| Name | SOLENO THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.12 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,762.89 / 9,010.81 |
| ข่าว, ประมาณการ, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Marine Parkway, Redwood City, CA, United States, 94065
Phone: 650 213 8444
Website: https://soleno.life
Employees: 182
Sector: Healthcare >> Biotechnology
Description: Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google